Qureator Organ-on-Chip Breakthrough Marks Milestone Under FDA Modernization Act 2.0 World’s First IND Approval in Oncology Based Solely on Human Vascularized Organoid Efficacy Data Confirms Shift Toward Human-Relevant Preclinical Testing…
In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market…
Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with a variety of frontotemporal dementia (FTD). In the pivot away from latozinemab,…
Sanofi’s $1.7 billion rare disease bet from last year has delivered a phase 2 win. In a midstage study, efdoralprin alfa beat the standard of care on primary and key…
Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy in a deal worth up to 1 billion euros (about $1.16 billion). The French pharma is…
Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes (PDF) $10.2 billion in milestones, puts the biologics at the center of…
Terns Pharmaceuticals has shelved its oral GLP-1 obesity candidate after a phase 2 trial delivered a mix of weight loss and tolerability data that fell short of expectations as well…
Five years after launching one of the most promising generative biology drug discovery companies, Generate Biomedicines, venture capital powerhouse Flagship Pioneering has brought a generative chemistry drug discovery company out…
Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the biotech’s just-launched pivotal trial for its rare disease candidate. Nextech and…
With $70 million and a phase 2 ready asset in hand, British biotech Elevara Medicines has emerged to try to revolutionize the treatment of rheumatoid arthritis. London-based Elevara was founded…